{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T10:59:33Z","timestamp":1697281173506},"reference-count":20,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[1999,12,1]],"date-time":"1999-12-01T00:00:00Z","timestamp":944006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biologicals"],"published-print":{"date-parts":[[1999,12]]},"DOI":"10.1006\/biol.1999.0229","type":"journal-article","created":{"date-parts":[[2002,10,7]],"date-time":"2002-10-07T11:57:37Z","timestamp":1033991857000},"page":"337-341","source":"Crossref","is-referenced-by-count":8,"title":["Assessment of Needs for Plasma for Fractionation in Europe"],"prefix":"10.1006","volume":"27","author":[{"given":"Johann J.","family":"Burckhardt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1006\/biol.1999.0229_RF1","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1046\/j.1537-2995.1994.34794330014.x","article-title":"Detection and characterization of hepatitis C virus RNA in immune globulins","volume":"34","author":"Yu","year":"1994","journal-title":"Transfusion"},{"key":"10.1006\/biol.1999.0229_RF2","first-page":"374","article-title":"Hepatitis C virus transmission by intravenous immunoglobulin","volume":"346","author":"James","year":"1995","journal-title":"Lancet"},{"key":"10.1006\/biol.1999.0229_RF3","first-page":"374","article-title":"Hepatitis C virus transmission by intravenous immunoglobulin","volume":"346","author":"Yu","year":"1995","journal-title":"Lancet"},{"key":"10.1006\/biol.1999.0229_RF4","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1046\/j.1423-0410.1999.7630175.x","article-title":"A second outbreak of Hepatitis C virus infection from anti-D immunoglobulin in Ireland","volume":"76","author":"Smith","year":"1999","journal-title":"Vox Sang"},{"key":"10.1006\/biol.1999.0229_RF5","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1046\/j.1423-0410.1999.7630138.x","article-title":"Transmission rates of Hepatitis C virus by different batches of a contaminated anti-D immunoglobulin preparation","volume":"76","author":"Lawlor","year":"1999","journal-title":"Vox Sang"},{"key":"10.1006\/biol.1999.0229_RF6","unstructured":"Quality and safety of plasma products, Brussels, 27 September 1994"},{"key":"10.1006\/biol.1999.0229_RF7","unstructured":"Committee for Proprietary Medicinal Products, Note for guidance on plasma-derived medicinal products, CPMP\/BWP\/269\/95, EMEA, 1998"},{"key":"10.1006\/biol.1999.0229_RF8","unstructured":"Committee for Proprietary Medicinal Products, Note for guidance on virus validation studies: the design, contribution and interpretation of studies validating the inactivation and removal of viruses, CPMP\/BWP\/268\/95, EMEA, 1998"},{"key":"10.1006\/biol.1999.0229_RF9","unstructured":"Committee for Proprietary Medicinal Products, Addendum to note for guidance on plasma-derived medicinal products. The introduction of nucleic acid amplification technology (NAT) for the detection of hepatitis C virus RNA in plasma pools, CPMP\/BWP\/390\/97, EMEA, 1998"},{"key":"10.1006\/biol.1999.0229_RF10","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1006\/biol.1998.0139","article-title":"Hepatitis A virus sequences detected in clotting factor concentrates associated with disease transmission","volume":"26","author":"Robertson","year":"1998","journal-title":"Biologicals"},{"key":"10.1006\/biol.1999.0229_RF11","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/(SICI)1096-9071(199902)57:2<91::AID-JMV1>3.0.CO;2-L","article-title":"A new cluster of hepatitis A infection in hemophiliacs traced to a contaminated plasma pool","volume":"57","author":"Chudy","year":"1999","journal-title":"J Med Virol"},{"key":"10.1006\/biol.1999.0229_RF12","first-page":"1103","article-title":"How much might the genome-amplification-testing reduce the probability of window donations in Switzerland? XXVth Congress of the International Society of Blood Transfusion (ISBT), Oslo, Norway, June 27\u2013July 2, 1998","volume":"74","author":"Burckhardt","year":"1998","journal-title":"Vox Sang"},{"key":"10.1006\/biol.1999.0229_RF13","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/jmv.1890370310","article-title":"Patterns of serological markers in transfusion-transmitted hepatitis C virus infection using second-generation HCV assays","volume":"37","author":"Lelie","year":"1992","journal-title":"J Med Virol"},{"key":"10.1006\/biol.1999.0229_RF14","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJM199606273342601","article-title":"The risk of transfusion-transmitted viral infections","volume":"334","author":"Schreiber","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1006\/biol.1999.0229_RF15","unstructured":"M\u00fcller-Breitkreuz, K, EPFA Working Group on Quality Assurance, Results of viral marker screening of unpaid blood donations and probability of window period donations in 1997, Vox Sang"},{"key":"10.1006\/biol.1999.0229_RF16","unstructured":"Kempf, C. Viral safety of Albumin SRC, HAEMO, April 1997"},{"key":"10.1006\/biol.1999.0229_RF17","series-title":"Intravenous Immunoglobulin Research and Therapy","first-page":"11","article-title":"Viral safety and manufacturing of an intravenous immunoglobulin","author":"Kempf","year":"1996"},{"key":"10.1006\/biol.1999.0229_RF18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.1365-3148.1999.009001003.x","article-title":"Assessment of the potential of plasma fractionation process to remove causative agentss of transmissible spongiform encephalopathy","volume":"9","author":"Foster","year":"1999","journal-title":"Transfusion Med"},{"key":"10.1006\/biol.1999.0229_RF19","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1046\/j.1365-2141.1996.d01-1679.x","article-title":"Detection of human parvovirus B19 DNA in plasma pools and blood products derived from these pools: implications for efficiency and consistency of removal of B19 DNA during manufacture","volume":"93","author":"Saldanha","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1006\/biol.1999.0229_RF20","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1046\/j.1537-2995.1997.37997454021.x","article-title":"Analysis of human plasma products: polymerase chain reaction does not discriminate between live and inactivated viruses","volume":"37","author":"Hilfenhaus","year":"1997","journal-title":"Transfusion"}],"container-title":["Biologicals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1045105699902294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1045105699902294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T06:20:37Z","timestamp":1557210037000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1045105699902294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,12]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1999,12]]}},"alternative-id":["S1045105699902294"],"URL":"https:\/\/doi.org\/10.1006\/biol.1999.0229","relation":{},"ISSN":["1045-1056"],"issn-type":[{"value":"1045-1056","type":"print"}],"subject":[],"published":{"date-parts":[[1999,12]]}}}